AI News NQ Analysis

Announcement of Appointment of Representative Director and Executive Officer COO at Blue Industries Inc.

Key facts

  • Announcement of Appointment of Representative Director and Executive Officer COO at Blue Industries Inc.
  • Blue Industries Inc. announces the appointment of Ryusuke Kuji as Representative Director and Masakazu Toda as Executive Officer and Chief Operating Officer (COO). Under this new leadership, the company will accelerate the expansion and adoption of its at-home cancer risk screening service, 'bluedrop'.
  • Source: PR TIMES
  • Date: Thu Jun 18 2026 00:30:01 GMT+0900 (Japan Standard Time)

Direct answer

Blue Industries Inc. announces the appointment of Ryusuke Kuji as Representative Director and Masakazu Toda as Executive Officer and Chief Operating Officer (COO). Under this new leadership, the company will accelerate the expansion and adoption of its at-home cancer risk screening service, 'bluedrop'.

Citation
Announcement of Appointment of Representative Director and Executive Officer COO at Blue Industries Inc. (Thu Jun 18 2026 00:30:01 GMT+0900 (Japan Standard Time)), PR TIMES
Source
PR TIMES
Date
Thu Jun 18 2026 00:30:01 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Blue Industries Inc. announces the appointment of Ryusuke Kuji as Representative Director and Masakazu Toda as Executive Officer and Chief Operating Officer (COO). Under this new leadership, the company will accelerate the expansion and adoption of its at-home cancer risk screening service, 'bluedrop'.

AI Analysis

Frequently Asked Questions

Q: Who has been appointed as CEO of Blue Industries?
A: Ryusuke Kuji, the founder, has been appointed as CEO.
Q: Which cancers can bluedrop detect?
A: It can assess risks for pancreatic, liver, lung, uterine, colorectal, breast, and prostate cancers.
Q: Can the test be completed at home?
A: Yes. Collect urine at home, send it via the kit, and view results on your smartphone.
Q: What is COO Masakazu Toda's background?
A: He has held executive roles at Takeda, Aker BioMarine Japan, and TCB Tokyo Central Aesthetic Surgery Group.
Q: What are the company's future business priorities?
A: Expanding into healthcare providers, health insurers, and corporate wellness programs.